Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{182034,
        author = {Dr. Tasneem Taj and Prof. Madan Godbole and Mrs. Shital Patil and Mr. Ranjeet Pandit and Ms. Ashwini Patil},
        title = {Clinical Research of Melatonin: Choice of Markers and Methods for Circadian Phase Assessment},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {2},
        pages = {659-660},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=182034},
        abstract = {A key modulator of circadian rhythms, melatonin may be used as a treatment for metabolic, neuropsychiatric, and sleep disorders. Our knowledge of the best biomarkers for circadian phase assessment and the clinical use of melatonin has improved as a result of recent clinical research (2023–2024). In this review, the most recent advancements in clinical research on melatonin are compiled, the choice of biomarkers, such as plasma melatonin and urinary 6-sulfatoxymelatonin (aMT6s), is critically assessed, and new approaches to circadian phase estimation, such as dim light melatonin onset (DLMO), actigraphy, and salivary assays, are examined.},
        keywords = {},
        month = {July},
        }